Abstract:Background: Dual therapy with aspirin and clopidogrel is the standard treatment for acute coronary syndrome (ACS). Dual antiplatelet therapy plays an important role in reducing major acute, short-and long-term adverse clinical outcomes. Currently, the economic evaluation of ticagrelor, a reversible and direct-acting oral antagonist of adenosine diphosphate receptor P2Y12 remains unknown. Objective: To compare the annual cost of ticagrelor versus branded clopidogrel in patients with ACS from a Malaysian health … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.